These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Doxycycline vs. macrolides in combination therapy for treatment of community-acquired pneumonia. Teh B; Grayson ML; Johnson PD; Charles PG Clin Microbiol Infect; 2012 Apr; 18(4):E71-3. PubMed ID: 22284533 [TBL] [Abstract][Full Text] [Related]
11. The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy. Charles PG; Whitby M; Fuller AJ; Stirling R; Wright AA; Korman TM; Holmes PW; Christiansen KJ; Waterer GW; Pierce RJ; Mayall BC; Armstrong JG; Catton MG; Nimmo GR; Johnson B; Hooy M; Grayson ML; Clin Infect Dis; 2008 May; 46(10):1513-21. PubMed ID: 18419484 [TBL] [Abstract][Full Text] [Related]
12. Diagnosis and management of community-acquired pneumonia in adults. Watkins RR; Lemonovich TL Am Fam Physician; 2011 Jun; 83(11):1299-306. PubMed ID: 21661712 [TBL] [Abstract][Full Text] [Related]
13. The clinical efficacy of fluoroquinolone and macrolide combination therapy compared with single-agent therapy against community-acquired pneumonia caused by Legionella pneumophila. Nakamura S; Yanagihara K; Izumikawa K; Seki M; Kakeya H; Yamamoto Y; Senjyu H; Saito A; Kohno S J Infect; 2009 Sep; 59(3):222-4. PubMed ID: 19592113 [No Abstract] [Full Text] [Related]
14. Q fever community-acquired pneumonia in a patient with Crohn's disease on immunosuppressive therapy. Nausheen S; Cunha BA Heart Lung; 2007; 36(4):300-3. PubMed ID: 17628200 [TBL] [Abstract][Full Text] [Related]
15. Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting. Segreti J; House HR; Siegel RE Am J Med; 2005 Jul; 118 Suppl 7A():21S-28S. PubMed ID: 15993674 [TBL] [Abstract][Full Text] [Related]
16. Macrolides are ideal for empiric therapy of community-acquired pneumonia in the immunocompetent host. Vergis EN; Yu VL Semin Respir Infect; 1997 Dec; 12(4):322-8. PubMed ID: 9436959 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. Dunbar LM; Khashab MM; Kahn JB; Zadeikis N; Xiang JX; Tennenberg AM Curr Med Res Opin; 2004 Apr; 20(4):555-63. PubMed ID: 15119993 [TBL] [Abstract][Full Text] [Related]
18. Monotherapy or combination therapy for hospitalized patients with community-acquired pneumonia: not yet the end of the story? Laterre PF Clin Infect Dis; 2008 May; 46(10):1510-2. PubMed ID: 18419483 [No Abstract] [Full Text] [Related]
19. [Lower tract infections as potential indication for therapy with macrolides]. Jahnz-Rózyk K; Targowski T Pol Merkur Lekarski; 2008 Nov; 25(149):426-8. PubMed ID: 19177781 [TBL] [Abstract][Full Text] [Related]
20. Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? Amsden GW J Antimicrob Chemother; 2005 Jan; 55(1):10-21. PubMed ID: 15590715 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]